Ahead of MetLife (MET) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Analysts on Wall Street project that MetLife (MET) will announce quarterly earnings of $2.19 per share in its forthcoming report, representing a decline of 4% year over year. Revenues are projected to reach $18.39 billion, declining 1.5% from the same quarter last year.The current level reflects a downward revision of 0.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.With that in mind, let's delve into the average projections of some MetLife metrics that are commonly tracked and projected by analysts on Wall Street.Analysts forecast 'Revenue- Premiums' to reach $11.29 billion. The estimate suggests a change of -2.9% year over year.The consensus estimate for 'Revenue- Other Revenues' stands at $656.89 million. The estimate points to a change of +3% from the year-ago quarter.Analysts' assessment points toward 'Revenue- Universal life and investment-type product policy fees' reaching $1.28 billion. The estimate indicates a year-over-year change of -0.4%.The average prediction of analysts places 'Revenue- Net investment income' at $5.13 billion. The estimate suggests a change of -1.4% year over year.Based on the collective assessment of analysts, 'Total Adjusted Revenue- Latin America' should arrive at $1.94 billion. The estimate indicates a change of +1.9% from the prior-year quarter.Analysts predict that the 'Adjusted Revenue- Corporate & other- Net investment income' will reach $76.29 million. The estimate indicates a year-over-year change of -19.7%.Analysts expect 'Total Adjusted Revenue- U.S. Business' to come in at $10.80 billion. The estimate indicates a change of -3.7% from the prior-year quarter.The collective assessment of analysts points to an estimated 'Total Adjusted Revenue- EMEA' of $726.53 million. The estimate suggests a change of +7.6% year over year.According to the collective judgment of analysts, 'Total Adjusted Revenue- Asia' should come in at $2.92 billion. The estimate suggests a change of +2.9% year over year.It is projected by analysts that the 'Adjusted Revenue- Asia- Net investment income' will reach $1.17 billion. The estimate indicates a change of +0.5% from the prior-year quarter.The consensus among analysts is that 'Adjusted Revenue- EMEA- Net investment income' will reach $57.66 million. The estimate indicates a change of +6.8% from the prior-year quarter.The combined assessment of analysts suggests that 'Adjusted Revenue- Latin America- Net investment income' will likely reach $412.51 million. The estimate suggests a change of +3.7% year over year. View all Key Company Metrics for MetLife here>>> MetLife shares have witnessed a change of -5.8% in the past month, in contrast to the Zacks S&P 500 composite's +2.3% move. With a Zacks Rank #4 (Sell), MET is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MetLife, Inc. (MET): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks